ImmunityBio Shares 11% Higher on License Application Resubmission for N-803
October 23 2023 - 10:00AM
Dow Jones News
By Dean Seal
Shares of ImmunityBio rose after the company resubmitted a
biological license application for its investigational bladder
cancer treatment N-803.
The stock was up 11% at $1.44 in early trading. Shares have
fallen 71% year-to-date.
The clinical-stage immunotherapy company said Monday that it
resubmitted the application to the U.S. Food and Drug
Administration.
The application is supported by the results of ImmunityBio's
studies in bladder cancer, including a study published last
November.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 23, 2023 10:45 ET (14:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From May 2023 to May 2024